Investment in First-in-Class anti-viral drug development

Synklino is a Danish biotechnology company creating a new pre-transplant intervention category. Its lead asset, SYN002, is a first-in-class ex vivo therapy designed to reduce both latent and active CMV directly in the donor organ before transplantation, addressing one of the most significant transplantation challenges. Synklino is owned by a group of private shareholders, including family offices and strategic investors.